AIxMed, an innovator in AI diagnostics for urine cytology and Lumea, a leading provider of primary clinical digital pathology solutions, announced a new partnership. This collaboration will integrate AIxMed's specialized AI technology into Lumea's FDA-cleared digital pathology platform, broadening the advanced diagnostic tools available to the urology market.

AIxMed's solution AIxURO is designed to assist in the analysis of non-invasive urine cytology specimens, aiming to improve diagnostic accuracy and workflow efficiency in bladder cancer assessment. AIxURO accurately identifies suspicious and atypical cells from a non-invasive urine sample incorporating The Paris System (TPS) for Reporting Urinary Cytology. These features are intended to support clinical decision-making, potentially reducing the frequency of invasive procedures like cystoscopies, enhancing patient compliance, and contributing to more cost effective healthcare.

"We are pleased to partner with AIxMed and add their expertise in urine cytology AI to our growing portfolio of AI solutions," said James Thackeray, CEO of Lumea. "This partnership reflects our ongoing commitment to integrating valuable AI capabilities that meet the specific needs of our diverse customer base and enhance diagnostic pathways."

"We recognize Lumea as a leader in providing an end-to-end solution for the urology market," said Samuel Chen, CEO of AIxMed. "We are excited to provide an integrated and tested solution within their platform allowing our mutual customers the ability to triage their cases, improve their QC, and make their work more efficient."

Lumea will integrate AIxURO into its established digital pathology ecosystem, which is utilized by a significant portion of the U.S. urology market. The addition of this urine cytology AI further diversifies Lumea's offerings for urologists and strengthens its support for comprehensive cancer diagnostic workflows